New Phase 3 trials registered, week of October 19, 2026: 2 industry trials
Industry sponsors registered 2 Phase 3 trials on ClinicalTrials.gov so far in the week of October 19 to 25, 2026. They plan to enroll 1,018 participants in all; the largest, Eli Lilly and Company's AMPLIFY-2 trial, plans to enroll 1,000.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, October 25, 2026.
The trials
- Eli Lilly registers Phase 3 study of EloraTZP in obesity and type 2 diabetes. Sponsor: Eli Lilly and Company. Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2. Interventions: eloralintide and tirzepatide, Tirzepatide. Phase: Phase 3. Planned enrollment: 1,000. Planned primary completion: October 2029. First posted October 19, 2026. Record: NCT07881458 (AMPLIFY-2).
- R-Pharm registers Phase 3 study of Goflikicept in pediatric FMF. Sponsor: R-Pharm. Conditions: Familial Mediterranean Fever, FMF. Intervention: RPH-104. Phase: Phase 3. Planned enrollment: 18. Planned primary completion: May 2029. First posted October 19, 2026. Record: NCT07880886.
By the numbers
- Trials: 2, from 2 lead sponsors.
- Planned enrollment: 1,018 in all across 2 trials; median 509 per trial.
- Largest: Eli Lilly and Company's AMPLIFY-2 trial, 1,000. Smallest: R-Pharm's RPH-104 trial, 18.
- Phases as registered: 2 Phase 3.
- Planned primary completion: from May 2029 to October 2029.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.